Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 1, pp 158–166 | Cite as

Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial)

  • Abhijeet Waghray
  • Nisheet Waghray
  • Adam T. Perzynski
  • Mark Votruba
  • M. Michael WolfeEmail author
Original Article

Abstract

Background

Proton pump inhibitors (PPIs) are potent inhibitors of acid secretion and are the mainstay of therapy for gastroesophageal reflux disease (GERD). Initially designed to be taken 30 min before the first daily meal, these agents are commonly used suboptimally, which adversely affects symptom relief. No study to date has assessed whether correcting dosing regimens would improve symptom control. The objective of this study was to determine whether patients with persistent GERD symptoms on suboptimal omeprazole dosing experience symptomatic improvement when randomized to commonly recommended dosing regimen and to evaluate the economic impact of suboptimal PPI dosing in GERD patients.

Methods

Patients with persistent heartburn symptoms ≥ 3 times per week treated with omeprazole 20 mg daily were enrolled and randomized to commonly recommended dosing or continued suboptimal dosing of omeprazole. The primary outcomes were changes in symptom, frequency, and severity, as determined using the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) 4 weeks after the intervention was administered. In secondary analysis, an alternative measure of symptom load was used to infer potential costs.

Results

Sixty-four patients were enrolled. GSAS symptom, frequency, and severity scores were significantly better when dosing was optimized for overall and heartburn-specific symptoms (P < 0.01 for all parameters). Cost savings resulting from reduced medical care and workplace absenteeism were estimated to be $159.60 per treated patient, with cost savings potentially exceeding $4 billion annually in the USA.

Discussion

Low-cost efforts to promote commonly recommended PPI dosing can dramatically reduce GERD symptoms and related economic costs.

ClinicalTrials.gov, number: NCT02623816.

Keywords

Gastroesophageal reflux disease Proton pump inhibitors Omeprazole Heartburn 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no financial or grant support or conflict of interest.

References

  1. 1.
    Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456.CrossRefGoogle Scholar
  2. 2.
    Jenkins SB, Leng BL, Shortland JR, et al. Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period. Adv Perit Dial Conf Perit Dial. 2001;17:191–195.Google Scholar
  3. 3.
    Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Therap. 2007;26:453–461.CrossRefGoogle Scholar
  4. 4.
    Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102:1259–1268.CrossRefGoogle Scholar
  5. 5.
    El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126:1692–1699.CrossRefGoogle Scholar
  6. 6.
    Association AG. The Burden of Gastrointestinal Diseases, vol. 2006. Bethesda, MD: AGA; 2001.Google Scholar
  7. 7.
    Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Therap. 2006;24:259–272.CrossRefGoogle Scholar
  8. 8.
    Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376–386.CrossRefGoogle Scholar
  9. 9.
    Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Therap. 1997;11:765–773.CrossRefGoogle Scholar
  10. 10.
    Guslandi M, Testoni PA, Passaretti S, et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. Hepato-gastroenterology. 1983;30:96–98.PubMedGoogle Scholar
  11. 11.
    Munson K, Garcia R, Sachs G. Inhibitor and ion binding sites on the gastric H, K-ATPase. Biochemistry. 2005;44:5267–5284.CrossRefGoogle Scholar
  12. 12.
    Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H + + K +)ATPase. Nature. 1981;290:159–161.CrossRefGoogle Scholar
  13. 13.
    Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.CrossRefGoogle Scholar
  14. 14.
  15. 15.
    Sachs G, Chang HH, Rabon E, et al. A nonelectrogenic H + pump in plasma membranes of hog stomach. J Biol Chem. 1976;251:7690–7698.PubMedGoogle Scholar
  16. 16.
    Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–1810.CrossRefGoogle Scholar
  17. 17.
    Donnellan C, Preston C, Moayyedi P, et al. WITHDRAWN: medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2010;2:003245.Google Scholar
  18. 18.
    Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118:S9–S31.CrossRefGoogle Scholar
  19. 19.
    Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. The American Journal of Gastroenterology. 2014;109:789–794.CrossRefGoogle Scholar
  20. 20.
    Toghanian S, Johnson DA, Stalhammar NO, et al. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: a post hoc analysis of the 2007 national health and wellness survey. Clin Drug Invest. 2011;31:703–715.CrossRefGoogle Scholar
  21. 21.
    Jacobson BC, Ferris TG, Shea TL, et al. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98:51–58.CrossRefGoogle Scholar
  22. 22.
    McDonagh MS, Carson S, Thakurta S. Drug Class Review: Proton Pump Inhibitors, vol. 5. Portland, OR: Final Report Update; 2009.Google Scholar
  23. 23.
    Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999;37:385–398.CrossRefGoogle Scholar
  24. 24.
    Sachs GPC, Hersey S. Acid Related Disorders Mystery to Mechanism: Mechanism to Management. Dominguez: SUSHU Communications Inc.; 1995.Google Scholar
  25. 25.
    Sharma BK, Walt RP, Pounder RE, et al. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984;25:957–964.CrossRefGoogle Scholar
  26. 26.
    Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–1110.CrossRefGoogle Scholar
  27. 27.
    Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108:905–911.CrossRefGoogle Scholar
  28. 28.
    Hungin AP, Rubin G, O’Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gener Pract. 1999;49:463–464.Google Scholar
  29. 29.
    Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease–where next? Aliment Pharmacol Therap. 2005;22:79–94.CrossRefGoogle Scholar
  30. 30.
    Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.CrossRefGoogle Scholar
  31. 31.
    Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–246.CrossRefGoogle Scholar
  32. 32.
    Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28:615–620.CrossRefGoogle Scholar
  33. 33.
    Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16:800-8e7.CrossRefGoogle Scholar
  34. 34.
    Metz DC, Inadomi JM, Howden CW, et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007;102:642–653.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Abhijeet Waghray
    • 1
  • Nisheet Waghray
    • 2
  • Adam T. Perzynski
    • 1
    • 4
  • Mark Votruba
    • 3
    • 4
  • M. Michael Wolfe
    • 1
    • 2
    Email author
  1. 1.Department of Medicine, MetroHealth Medical CenterCase Western Reserve UniversityClevelandUSA
  2. 2.Division of Gastroenterology, MetroHealth Medical CenterCase Western Reserve UniversityClevelandUSA
  3. 3.Department of EconomicsCase Western Reserve UniversityClevelandUSA
  4. 4.Center for Healthcare Research and PolicyCase Western Reserve UniversityClevelandUSA

Personalised recommendations